Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis

Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis

Abstract Background We aimed to compare neuropathic progression rate between hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and other peripheral neuropathies, including diabetic peripheral neuropathy (DPN) and Charcot-Marie-Tooth disease (CMT). Methods Literature searches identi...

Full description

Bibliographic Details
Main Authors:	Xiaochen Lin, Aaron Yarlas, Montserrat Vera-Llonch, Nishtha Baranwal, Josh Biber, Duncan Brown, Braden Vogt, Chafic Karam
Format:	Article
Language:	English
Published:	BMC 2021-02-01
Series:	BMC Neurology
Subjects:	Hereditary transthyretin amyloidosis with polyneuropathy Neuropathy impairment score Meta-analysis Peripheral neuropathy Neuropathic progression
Online Access:	https://doi.org/10.1186/s12883-021-02094-y

Similar Items

The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
by: Aaron Yarlas, et al.
Published: (2023-03-01)

Transthyretin-Related Familial Amyloid Polyneuropathy: In the Light of New Developments
by: Arman Çakar, et al.
Published: (2017-09-01)

Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines
by: Benson MD, et al.
Published: (2020-08-01)

Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort
by: Nath Pasutharnchat, et al.
Published: (2021-05-01)

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
by: Faruk Uğur Doğan, et al.
Published: (2019-03-01)

Hereditary transthyretin amyloidosis: a case report
by: Angela Lee, et al.
Published: (2022-06-01)

Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology
by: Volha Skrahina, et al.
Published: (2021-01-01)

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
by: Dixon S, et al.
Published: (2023-11-01)

Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS)
by: Márcia Waddington Cruz, et al.

Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management
by: Vélez-Santamaría V, et al.
Published: (2022-12-01)

Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
by: Márcia Waddington-Cruz, et al.
Published: (2019-02-01)

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
by: Falcão de Campos C, et al.
Published: (2023-02-01)

Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy
by: Alejandra González‐Duarte, et al.
Published: (2020-03-01)

Guideline of transthyretin-related hereditary amyloidosis for clinicians
by: Ando Yukio, et al.
Published: (2013-02-01)

Skeletal Muscle Involvement Pattern of Hereditary Transthyretin Amyloidosis: A Study Based on Muscle MRI
by: Xujun Chu, et al.
Published: (2022-05-01)

Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey
by: Juan González-Moreno, et al.
Published: (2023-12-01)

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update
by: Angela Dispenzieri, et al.
Published: (2022-06-01)

A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
by: Luca Gentile, et al.
Published: (2023-11-01)

Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years
by: Giampaolo Merlini, et al.
Published: (2020-02-01)

Vitreous Amyloidosis as the Presenting Symptom of Familial Amyloid Polyneuropathy TTR Val30Met in a Portuguese Patient
by: Mariana Seca, et al.
Published: (2014-03-01)

Late-onset familial amyloidosis polyneuropathy associated with c.186G>C in transthyretin
by: Eugenia Conti, et al.
Published: (2024-03-01)

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data
by: Nicholas J. Viney, et al.
Published: (2021-02-01)

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
by: Ivan Urits, et al.
Published: (2020-08-01)

Familial Amyloid Polyneuropathy Misdiagnosed as Systemic Sclerosis
by: Marcia Agostinho Pereira, et al.
Published: (2022-01-01)

Early-Onset of Transthyretin Amyloidosis in a Young Afro-Caribbean Woman With Thr60Ala Mutation
by: Stormy C. Keppel, MD, et al.
Published: (2020-11-01)

Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy
by: Marcus Vinicius Pinto, et al.

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care
by: Luigetti M, et al.
Published: (2020-02-01)

Late-Onset Hereditary Transthyretin Amyloidosis Val30Met in an Elderly Person in a Non-Endemic Area
by: Wang S, et al.
Published: (2022-06-01)

Phenotypic expressions of hereditary Transthyretin Ala97Ser related Amyloidosis (ATTR) in Taiwanese
by: Hui-Ching Hsu, et al.
Published: (2017-09-01)

Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca
by: E. Cisneros-Barroso, et al.
Published: (2023-08-01)

Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features
by: Zoltán Pozsonyi, et al.
Published: (2021-07-01)

Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study
by: Mónica Inês, et al.
Published: (2020-03-01)

Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
by: Leslie Amass, et al.
Published: (2018-12-01)

Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm
by: Yoshiki Sekijima, et al.
Published: (2018-01-01)

Diagnostic algorithm in transthyretin amyloidosis with cardiomyopathy
by: Mariana Gospodinova, et al.
Published: (2020-07-01)

Current Evidence Supporting the Role of Immune Response in ATTRv Amyloidosis
by: Domenico Plantone, et al.
Published: (2023-09-01)

Hereditary systemic transthyretin amyloidosis: a clinical case and an opinion on the problem
by: A. S. Draganova, et al.
Published: (2019-07-01)

New simple and quick method to analyze serum variant transthyretins: direct MALDI method for the screening of hereditary transthyretin amyloidosis
by: Toshiya Nomura, et al.
Published: (2019-05-01)

Gait Characterization and Analysis of Hereditary Amyloidosis Associated with Transthyretin Patients: A Case Series
by: Maria do Carmo Vilas-Boas, et al.
Published: (2022-07-01)

Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis
by: Hiroki Yamaguchi, et al.
Published: (2022-03-01)